Glancy Prongay Wolke & Rotter LLP reminded investors of an October 5, 2026, deadline to file a lead-plaintiff motion in a proposed securities class action involving Replimune Group, Inc. The action covers investors who purchased or otherwise acquired Replimune securities between October 20, 2025, and April 10, 2026, inclusive. The complaint alleges that the company and other defendants made materially false or misleading statements and failed to disclose deficiencies in the clinical studies supporting its Biologics License Application for RP1 combined with nivolumab. On April 10, 2026, the U.S. Food and Drug Administration rejected the application in a Complete Response Letter, citing deficiencies in the RPL-001-16 and RP1-104 studies and saying an early unplanned analysis from RP1-104 included only 40 patients, or 10% of planned enrollment. Replimune shares fell $1.15, or 19.46%, to close at $4.76 on April 10 before trading was halted, then fell another $3.06, or 64.29%, to close at $1.70 on April 13 after the company discussed the FDA response. Investors do not need to take action to remain absent members of the class and may retain counsel of their choice or take no action.